LipoScience to Present at Barclays Global Healthcare Conference

        Print
| Source: LipoScience, Inc.

RALEIGH, N.C., Feb. 27, 2014 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that Howard Doran, President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 11:15 A.M. ET on Wednesday, March 12, 2014, in Miami, FL.

The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://investor.liposcience.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.

About LipoScience, Inc.

LipoScience, Inc. (Nasdaq:LPDX) is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile® test, the Company's first proprietary test, is an FDA-cleared blood test that directly quantifies LDL particles and provides physicians and their patients with actionable information to personalize management of heart disease. To date, more than 11 million NMR LipoProfile tests have been ordered. LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for the management of cardiovascular disease

The Vantera® Clinical Analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Investor Relations
ICR, Inc.
Bob Yedid
Senior Vice President
646-277-1247


LipoScience, Inc.
Tori Hall

(919) 256-1046